Draupnir Bio

Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cells own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins 40% of the human proteome untouched. At...

Biotechnology,biotech,targeted protein degradation,membrane-bound proteins,extracellular targets,and lysosome

Draupnir bio operates in the Biotechnology research industry.

Draupnir bio's revenue is 11m - 100m

Draupnir bio has 11 - 50 employees.